Latest & greatest articles for pregabalin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pregabalin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pregabalin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pregabalin

1. Trial of Pregabalin for Acute and Chronic Sciatica. Full Text available with Trip Pro

Trial of Pregabalin for Acute and Chronic Sciatica. Sciatica can be disabling, and evidence regarding medical treatments is limited. Pregabalin is effective in the treatment of some types of neuropathic pain. This study examined whether pregabalin may reduce the intensity of sciatica.We conducted a randomized, double-blind, placebo-controlled trial of pregabalin in patients with sciatica. Patients were randomly assigned to receive either pregabalin at a dose of 150 mg per day that was adjusted (...) underwent randomization, of whom 108 received pregabalin and 101 received placebo; after randomization, 2 patients in the pregabalin group were determined to be ineligible and were excluded from the analyses. At week 8, the mean unadjusted leg-pain intensity score was 3.7 in the pregabalin group and 3.1 in the placebo group (adjusted mean difference, 0.5; 95% confidence interval [CI], -0.2 to 1.2; P=0.19). At week 52, the mean unadjusted leg-pain intensity score was 3.4 in the pregabalin group and 3.0

2017 NEJM Controlled trial quality: predicted high

2. Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April

Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April As of 1 April 2019, pregabalin and gabapentin are controlled under the Misuse (...) of Drugs Act 1971 as Class C substances and scheduled under the Misuse of Drugs Regulations 2001 as Schedule 3. Evaluate patients carefully for a history of drug abuse before prescribing pregabalin and gabapentin and observe patients for development of signs of abuse and dependence. Published 16 April 2019 From: Therapeutic area: , , , Contents Advice for healthcare professionals: to reflect growing concern about abuse, both pregabalin and gabapentin are now classified as Class C controlled substances

2019 MHRA Drug Safety Update

3. Effect of Gabapentin vs Pregabalin on Pain Intensity in Adults WIth Chronic Sciatica: A Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Gabapentin vs Pregabalin on Pain Intensity in Adults WIth Chronic Sciatica: A Randomized Clinical Trial. Optimal pharmacologic treatment for chronic sciatica (CS) is currently unclear. While gabapentin (GBP) and pregabalin (PGB) are both used to treat CS, equipoise exists. Nevertheless, pharmaceutical regulation authorities typically subsidize one drug over the other. This hinders interchange wherever the favored drug is either ineffective or ill-tolerated.To assess GBP vs PGB head

2018 JAMA neurology Controlled trial quality: predicted high

4. Anxiously Awaiting Evidence: Pregabalin in generalized anxiety disorder

Anxiously Awaiting Evidence: Pregabalin in generalized anxiety disorder Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,800 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research (...) . www.acfp.ca July 16, 2018 Anxiously Awaiting Evidence: Pregabalin in generalized anxiety disorder Clinical Question: Is pregabalin effective for generalized anxiety disorder (GAD)? Bottom Line: Evidence for pregabalin in GAD is inconsistent and at high-risk of bias (industry-written, short-term, poorly described methods, high drop-outs, and run-in periods that overinflate benefit). If real, an additional one in 6-8 people may respond to pregabalin compared to placebo at 4-8 weeks. However, the change

2018 Tools for Practice

5. Perioperative Pregabalin and Intraoperative Lidocaine Infusion to Reduce Persistent Neuropathic Pain After Breast Cancer Surgery: A Multicenter, Factorial, Randomized, Controlled Pilot Trial (Abstract)

Perioperative Pregabalin and Intraoperative Lidocaine Infusion to Reduce Persistent Neuropathic Pain After Breast Cancer Surgery: A Multicenter, Factorial, Randomized, Controlled Pilot Trial Persistent postsurgical pain is defined as pain localized to the area of surgery of a duration of ≥2 months and is, unfortunately, a common complication after breast cancer surgery. Although there is insufficient evidence to support any preventative strategy, prior literature suggests the possible efficacy (...) of intravenous lidocaine and perioperative pregabalin in preventing persistent pain after surgery. To determine feasibility of conducting a larger definitive trial, we conducted a multicenter 2 × 2 factorial, randomized, placebo-controlled pilot trial of 100 female patients undergoing breast cancer surgery. Patients were randomized to receive an intraoperative lidocaine infusion (1.5 mg/kg bolus followed by 2 mg/kg/h) or placebo and perioperative pregabalin (300 mg preoperatively, 75 mg twice daily for 9

2019 EvidenceUpdates

6. Pregabalin

Pregabalin Top results for pregabalin - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for pregabalin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

7. Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: findings from a cost-consequences analysis in a nested case-control study

Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: findings from a cost-consequences analysis in a nested case-control study Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: findings from a cost-consequences analysis in a nested case-control study Pregabalin and gabapentin in matched patients with peripheral neuropathic pain (...) was to assess the costs and benefits of pregabalin and gabapentin, for the treatment of adults with peripheral neuropathic pain, in routine medical practice. The authors concluded that pregabalin seemed to reduce the mean weekly intensity of pain more than gabapentin, with no significant difference in costs. The reporting and methods were satisfactory. The authors' conclusion appears to be appropriate, but highly uncertain. Type of economic evaluation Cost-effectiveness analysis, cost-utility analysis Study

2010 NHS Economic Evaluation Database.

8. Pregabalin vs duloxetine for treating diabetic peripheral neuropathic pain: a meta-analysis

Pregabalin vs duloxetine for treating diabetic peripheral neuropathic pain: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

9. Pregabalin Zentiva k.s. - neuropathic pain, epilepsy, generalised anxiety disorder

Pregabalin Zentiva k.s. - neuropathic pain, epilepsy, generalised anxiety disorder 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 15 December 2016 EMA/14344/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment (...) report Pregabalin Zentiva k.s. International non-proprietary name: pregabalin Procedure No. EMEA/H/C/004277/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Assessment report EMA/14344/2017 Page 2/22 Table of contents 1. Background information on the procedure 5 1.1. Submission of the dossier 5 1.2. Steps taken for the assessment of the product 6 2. Scientific discussion 7 2.1. Introduction 7 2.2. Quality aspects 7 2.2.1

2017 European Medicines Agency - EPARs

10. Gabapentin and pregabalin: major adverse effects

Gabapentin and pregabalin: major adverse effects Prescrire IN ENGLISH - Spotlight ''Gabapentin and pregabalin: major adverse effects'', 1 November 2014 {1} {1} {1} | | > > > Gabapentin and pregabalin: major adverse effects Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Gabapentin and pregabalin: major adverse effects To reduce the consequences (...) of some severe adverse effects associated with gabapentin or pregabalin, it is advisable not to expose patients to them other than in situations where these drugs have proved to be highly effective. Gabapentin and pregabalin are used in certain epilepsies and for pain in neurological diseases. Pregabalin is also used to treat anxiety disorders. According to a review of French pharmacovigilance data published in 2013, between 1995 and 2009, 2415 adverse effects linked to gabapentin or pregabalin were

2014 Prescrire

11. Gabapentin and pregabalin: Are high doses justified?

Gabapentin and pregabalin: Are high doses justified? Gabapentin and pregabalin: Are high doses justified? January 2019 Mailing Address: Therapeutics Initiative The University of British Columbia Department of Anesthesiology, Pharmacology & Therapeutics 2176 Health Sciences Mall Vancouver, BC Canada V6T 1Z3 Tel.: 604 822 0700 Fax: 604 822 0701 E-mail: info@ti.ubc.ca www.ti.ubc.ca 117 A nalgesia once seemed a relatively straightfor- ward aspect of medicine. Recommendations in textbooks (...) and guidelines were definitive, albeit heavily conflicted. Even recent guidelines encourage dose titration, based on an implicit, if unsupported, notion that more is likely to be better. 1 Recent experiments and systematic reviews show that drugs seldom outperform placebo significantly in chronic pain. Even old standards like acetaminophen and amitriptyline do not stand up well to careful scru- tiny of randomized placebo-controlled trials. 2,3 Recent evidence confirms that gabapentin and pregabalin

2019 Therapeutics Letter

12. Pregabalin for decreasing pancreatic pain in chronic pancreatitis. Full Text available with Trip Pro

Pregabalin for decreasing pancreatic pain in chronic pancreatitis. Chronic abdominal pain is one of the major symptoms in people with chronic pancreatitis. The role of pregabalin in people with chronic pancreatic pain due to chronic pancreatitis is uncertain.To assess the benefits and harms of pregabalin in people with chronic abdominal pain due to chronic pancreatitis.We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library 2015, issue 6, and MEDLINE (...) difference (MD) with 95% confidence intervals (CI) with RevMan 5, based on intention-to-treat analysis.Only one study, funded by Pfizer, met the inclusion criteria for the review. A total of 64 participants (with chronic pain due to chronic pancreatitis) were randomly assigned to receive escalating doses of pregabalin (150 mg per day to 600 mg per day; 34 participants) or matching placebo (30 participants). Participants received pregabalin or placebo for three weeks on an outpatient basis; the outcomes

2016 Cochrane

13. Systematic review and meta-analysis: Pregabalin is effective in reducing fibromyalgia pain

Systematic review and meta-analysis: Pregabalin is effective in reducing fibromyalgia pain Pregabalin is effective in reducing fibromyalgia pain | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Pregabalin is effective in reducing fibromyalgia pain Article Text Therapeutics/Prevention Systematic review and meta-analysis Pregabalin is effective in reducing fibromyalgia pain Charles Argoff Statistics from Altmetric.com Commentary on: Derry

2017 Evidence-Based Medicine

14. A combination pharmacotherapy of tapentadol and pregabalin to tackle centrally driven Osteoarthritis pain. Full Text available with Trip Pro

A combination pharmacotherapy of tapentadol and pregabalin to tackle centrally driven Osteoarthritis pain. Many Osteoarthritis (OA) patients report with clinical features to their pain that cannot be explained by purely peripheral mechanisms. Yet, the analgesic agents available that tackle centrally driven chronic pain often provide only partial pain relief, or have dose-limiting side effects. We explored a combination therapy of the centrally acting analgesic agents tapentadol and pregabalin (...) , to investigate if they could be used in combination to provide superior analgesia.Using electrophysiological single-unit recordings taken from spinal wide dynamic range (WDR) neurons, Diffuse Noxious Inhibitory Controls (DNIC) were assessed as a marker of potential changes in descending controls in a monoiodoacetate (MIA) model of OA. We investigated if a subcutaneous injection of tapentadol or pregabalin, both alone and in combination, inhibited neuronal responses and restored the expression of DNIC

2019 European Journal of Pain

15. Pregabalin for pain in fibromyalgia in adults. Full Text available with Trip Pro

Pregabalin for pain in fibromyalgia in adults. This review updates part of an earlier Cochrane review on 'Pregabalin for acute and chronic pain in adults' (Moore 2009), and considers only fibromyalgia pain.Antiepileptic drugs have been used in pain management since the 1960s. Pregabalin is an antiepileptic drug also used in management of chronic pain conditions, including fibromyalgia. Pain response with pregabalin is associated with major benefits for other symptoms, and improved quality (...) of life and function in people with chronic painful conditions.To assess the analgesic efficacy and adverse events of pregabalin for pain in fibromyalgia in adults, compared with placebo or any active comparator.We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and EMBASE for randomised controlled trials from inception to May 2009 for the original review and to 16 March 2016 for this update. We also searched the reference lists of retrieved studies and reviews

2016 Cochrane Controlled trial quality: predicted high

16. Abuse and Misuse Potential of Pregabalin: A Review of the Clinical Evidence

Abuse and Misuse Potential of Pregabalin: A Review of the Clinical Evidence Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources and a summary of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses (...) : This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Abuse and Misuse Potential of Pregabalin: A Review of the Clinical Evidence DATE: 24 April 2012 CONTEXT AND POLICY ISSUES Pregabalin (Lyrica) is an anticonvulsant approved in Canada and the United States (US) since 2005 to treat neuropathic pain

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

17. Comparison of Pregabalin and Sodium Valproate in Migraine Prophylaxis: A Randomized Double-Blinded Study. (Abstract)

Comparison of Pregabalin and Sodium Valproate in Migraine Prophylaxis: A Randomized Double-Blinded Study. Patients suffering from headache, particularly migraine type, are among the most dissatisfied patients. The aim of this study was comparing the efficacy of pregabalin with valproate sodium, in preventing migraine headache. In a randomized, double-blinded study, adult patients eligible for prophylactic treatment (i.e., patients with 4-15 attacks per month in last two months) were recruited (...) . Patients' demographic data, duration of symptoms, headache frequency (attacks per month) and intensity (based on visual analogue scale) and also drugs used to relief headache were recorded. The patients were randomly assigned to two groups; valproate sodium (200 mg two times daily) and pregabalin (50 mg two times daily). The patients were examined by neurology specialist monthly for three months and the related data were recorded. The Data were analyzed using SPSS version 21, with related statistical

2018 Iranian journal of pharmaceutical research : IJPR Controlled trial quality: uncertain

18. Pregabalin Does Not Decrease the Pain of Sciatica. (Abstract)

Pregabalin Does Not Decrease the Pain of Sciatica. 28925674 2018 12 11 2018 12 11 1532-0650 96 4 2017 Aug 15 American family physician Am Fam Physician Pregabalin Does Not Decrease the Pain of Sciatica. 260 Ebell Mark H MH University of Georgia, Athens, GA, USA. eng Journal Article Randomized Controlled Trial United States Am Fam Physician 1272646 0002-838X 0 Analgesics 55JG375S6M Pregabalin AIM IM Analgesics therapeutic use Double-Blind Method Humans Middle Aged Pain drug therapy Pain (...) Measurement Pregabalin therapeutic use Sciatica drug therapy 2017 9 20 6 0 2017 9 20 6 0 2018 12 12 6 0 ppublish 28925674 d13436

2018 American Family Physician Controlled trial quality: uncertain

19. The possible Preventive Role of Pregabalin in Post-mastectomy Pain Syndrome: A Double-Blinded Randomized Controlled Trial. Full Text available with Trip Pro

The possible Preventive Role of Pregabalin in Post-mastectomy Pain Syndrome: A Double-Blinded Randomized Controlled Trial. Chronic postmastectomy pain syndrome (PMPS) has a considerable negative impact on the quality of life of breast cancer patients.The objective of this study was to assess the possible preventive role of perioperative pregabalin in PMPS.This randomized controlled study included 200 patients with breast cancer scheduled for elective breast cancer surgery. They were randomly (...) assigned to one of two treatment groups. The pregabalin group received 75 mg of pregabalin twice daily for seven days and the control group received oral equivalent placebo capsules. The primary outcome was development of neuropathic PMPS. Neuropathic pain was assessed using the Grading System for Neuropathic Pain. Secondary outcome measures were safety and Visual Analogue Scale scores.Neuropathic pain was significantly less frequent in the pregabalin group compared to the control group at four weeks

2018 Journal of pain and symptom management Controlled trial quality: predicted high

20. Pregabalin and Speech Pathology Combination Therapy for Refractory Chronic Cough: A Randomized Controlled Trial (Abstract)

Pregabalin and Speech Pathology Combination Therapy for Refractory Chronic Cough: A Randomized Controlled Trial Chronic refractory cough (CRC) is a difficult problem to treat. Speech pathology treatment (SPT) improves symptoms but resolution is incomplete. Centrally acting neuromodulators also improve cough symptoms, but not cough reflex sensitivity, and the effect is short-lived. We hypothesized that combined SPT and centrally acting neuromodulators would have a superior outcome than SPT alone (...) . Our goal was to determine whether combined pregabalin and SPT is more effective than SPT alone.Randomized placebo controlled trial. Forty patients with CRC were randomly assigned to receive either combined SPT and pregabalin 300 mg daily or combined SPT and placebo. Outcome measures were collected at baseline, end of treatment, and 4 weeks after the end of treatment. Primary outcome measures were cough frequency using the Leicester Cough Monitor, cough severity using a visual analog scale

2016 EvidenceUpdates Controlled trial quality: predicted high